MOCHIDA PHARMACEUTICAL CO., LTD.

The present invention provides alginic acid derivatives represented by formula (I) and formula (II), and a novel crosslinked alginic acid obtained by carrying out a Huisgen reaction using an alginic acid derivative of formula (I) and an alginic acid derivative of formula (II). There are thereby provided novel alginic acid derivatives and a novel crosslinked alginic acid.

Provided are novel alginic acid derivatives and a novel crosslinked alginic acid. The alginic acid derivatives are represented by formula (I) and formula (II). The novel crosslinked alginic acid obtained by Huisgen reaction using an alginic acid derivative of formula (I) and an alginic acid derivative of formula (II).

The present invention provides alginic acid derivatives represented by formula (I) and formula (II), and a novel crosslinked alginic acid obtained by carrying out a Huisgen reaction using an alginic acid derivative of formula (I) and an alginic acid derivative of formula (II). There are thereby provided novel alginic acid derivatives and a novel crosslinked alginic acid.

The present disclosure provides suspendable ophthalmic solutions with excellent redispersibility. The present disclosure provides an aqueous suspension agent comprising (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, a cellulosic polymer, and a nonionic surfactant.

Provided are a novel crosslinked alginic acid, a crosslinked alginic acid structure, etc., by performing a crosslinking reaction using alginic acid derivatives represented by formula (I) and formula (II). As a result, a novel crosslinked alginic acid, crosslinked alginic acid structure, etc., are provided.

[Problem] To provide an additional use of a polysaccharide derivative such as a tissue adhesive material [Solution] According to some embodiments, a tissue adhesive material is provided, which is intended to be used for a hard and thick tissue and/or a connective tissue and comprises a polysaccharide derivative having such a structure that a group represented by formula (A) is introduced in an acidic, basic or amphoteric polysaccharide. According to some embodiments, a crosslinked structure and a tissue adhesive material comprising the crosslinked structure are provided, in which the crosslinked structure comprises (a) a polysaccharide derivative having such a structure that a group represented by formula (A) is introduced into an acidic, basic or amphoteric polysaccharide and (b) at least one of an amino-group-containing polymer and an amino-group-containing low-molecular-weight compound each containing at least two primary amino groups, hydrazide groups or aminooxy groups and a group represented by formula (x1), and the crosslinking is achieved by the covalent bonding between a primary amino group, a hydrazide group or an aminooxy group contained in the amino-group-containing polymer and the amino-group-containing low-molecular-weight compound and the group represented by formula (A) contained in the polysaccharide derivative through a Schiff base. According to some embodiments, a tissue adhesive material having a gel-like form is provided, which comprises a polysaccharide derivative having such a structure that a group represented by formula (A-2) is introduced into a polysaccharide containing an amino group, in which the group represented by formula (A-2) is introduced into the polysaccharide by substituting for a hydrogen atom in the amino group in the polysaccharide to form an amide bond.

The present invention provides: a freeze-dried composition which comprises (a) a monovalent metal alginate and (b) a salt selected from a monovalent metal salt and an ammonium salt; and a method of producing a freeze-dried monovalent metal alginate composition which comprises the steps of freezing an aqueous solution formed by dissolving at least the component (a) and the component (b), performing first drying, and then performing second drying as desired to reduce a water content to 3% by mass or less. This is a freeze-dried monovalent metal alginate composition with suppressed viscosity decrease with the lapse of time.

It is desirable to provide a novel biomaterial and the like for tendon repair. Provided is a biomaterial for tendon repair containing a hydrogel formed by means of a cross-linking reaction between a reactive group A and a reactive group B, wherein the hydrogel contains a water-soluble polymer having the reactive group A, and mesenchymal stem cells having the reactive group B.

There has been required a novel and practicable multilayer structure that has enhanced structure stability and, therefore, is improved in the enlargement of device size, easiness in processing, etc. A structure according to the present invention that comprises a core layer comprising a pharmacological ingredient embedded in a chemically crosslinked alginic acid, a cationic polymer layer coating the core layer, and an anionic polymer layer coating the cationic polymer layer.

The present invention provides a ready-to-use sterile alginate aqueous solution preparation which is packed in a sealed container or an airtight container and which has storage stability, comprising: (a) a low-endotoxin monovalent metal salt of alginic acid having a weight average molecular weight of 50,000 to 400,000 by a GPC-MALS method; (b) a salt selected from a monovalent metal salt and an ammonium salt; and (c) water, wherein a concentration of the component (a) is 1.5% by mass or more, a concentration of the component (b) is 0.5 to 2% by mass, and a viscosity measured at 20° C. using a rotational viscometer is 2700 mPa·s or more, and a method of producing the same. This alginate aqueous solution preparation is a ready-to-use aqueous solution preparation of a low-endotoxin monovalent metal salt of alginic acid.